Skip to main content
. 2020 May 7;12(5):1179. doi: 10.3390/cancers12051179

Table 1.

Post-translational modifications of Rho GTPases.

PTMs Rho GTPase Regulator Target Site Effects Refs
Phosphorylation RhoA PKA S188 Increasing interaction with RhoGDI [21,22]
Decreases binding to ROCK effector
Protection of RhoA from degradation
PKG S188 Translocation to the cytosol [23]
Protection of RhoA from degradation
PKC T127 and S188 Translocation to the plasma membrane [24]
Protection of RhoA from degradation
c-Met Tyr42 Proteasomal degradation [25]
Rac1 ERK T108 RAC1 for translocation to the nucleus [26]
FAK Y64 Inhibit RAC1 activity [27]
SRC Y64 Inhibit RAC1 activity [27]
AKT S71 Inhibits RAC1 activity [28]
Cdc42 SRC Y64 Increasing interaction with RhoGDI [29]
PKA S185 Increasing interaction with RhoGDI [30]
Ubiquitination RhoA SMURF1 K6,K7 and K51 Proteasomal degradation [31]
SCF K135 Proteasomal degradation in a ERK-dependent manner [32]
CUL3 ND Proteasomal degradation of GDP-bound inactive RhoA [33]
Rac1 XIAP and clAP1 K147 Proteasomal degradation [34]
HACE1 K147 Targets GTP-bound, active RAC1 for degradation [35]
SCF K166 Proteasomal degradation in a AKT-dependent manner [36]
Transglutamination RhoA CNF1 E63 Constitutive activation [37]
Rac1 CNF1 E61 Constitutive activation [37]
Cdc42 CNF1 E61 Constitutive activation [37]
AMPylation RhoA HYPE T37 Suppress effector binding [38]
Rac1 HYPE T35 Suppress effector binding [38]
Cdc42 HYPE T35 Suppress effector binding [38]
SUMOylation Rac1 PIAS3 K183,K184,K186 and K188 Increased GTP binding and RAC1 activation [39,40]